Efficacy of Second-Line Biological Therapies in Moderate to Severe Ulcerative Colitis Patients with Prior Failure of Anti-Tumor Necrosis Factor Therapy: A Multi-Center Study
Based on real-world data, second-line biological therapy with ustekinumab, vedolizumab, and tofacitinib showed comparable efficacy in patients with moderate to severe UC with prior exposure to anti-TNF therapy.
Authors
- Seung Bum Lee (ORCID: https://orcid.org/0000-0003-2196-6296)
- Jong-Yoon Lee (ORCID: https://orcid.org/0009-0003-3867-2435)
- Jong‐Hoon Lee (ORCID: https://orcid.org/0000-0003-1775-5656)
- Ji-Eun Na
- Tae Oh Kim (ORCID: https://orcid.org/0000-0002-7359-1599)
- Yong-Eun Park (ORCID: https://orcid.org/0000-0001-6882-2973)
- Su Bum Park (ORCID: https://orcid.org/0000-0003-1573-2792)
- Jongha Park (ORCID: https://orcid.org/0000-0002-5241-1747)
- Seung-Min Hong (ORCID: https://orcid.org/0000-0002-5289-8487)
Institutions
- Ulsan College (KR)
- University of Ulsan (KR)
- Inje University Haeundae Paik Hospital (KR)
- Pusan National University Hospital (KR)
- Ulsan University Hospital (KR)
- Pusan National University Yangsan Hospital (KR)
- Dong-A University (KR)
Publication Details
- Journal
- Journal of Personalized Medicine
- Published
- 2024-10-18
- DOI
- https://doi.org/10.3390/jpm14101066
- Citations
- 3
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.65
Funders
- Inje University